Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Бактериальный вагиноз: современные представления о диагностике и лечении
Бактериальный вагиноз: современные представления о диагностике и лечении
Уруймагова А.Т., Прилепская В.Н., Межевитинова Е.А., Донников А.Е., Иванова А.А. Бактериальный вагиноз: современные представления о диагностике и лечении. Гинекология. 2021; 23 (4): 286–293.
DOI: 10.26442/20795696.2021.4.200954
DOI: 10.26442/20795696.2021.4.200954
DOI: 10.26442/20795696.2021.4.200954
________________________________________________
DOI: 10.26442/20795696.2021.4.200954
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Микробиота – совокупность микроорганизмов человека, которые существуют с ним в норме и при патологии, участвуют в физиологических и патофизиологических реакциях, метаболизме. Классическим проявлением нарушения микробиоты влагалища является клинический невоспалительный синдром – бактериальный вагиноз (БВ), характеризующийся определенными изменениями состава микробиоты влагалища и чрезмерным размножением микроорганизмов, присутствующих в норме в незначительном количестве. В настоящее время данные литературы подчеркивают, что вопросы этиологии, патогенеза БВ, причины рецидивирования процесса до конца не изучены, неизвестны причины отсутствия отдаленной эффективности терапии БВ. Дальнейшие исследования в данной области должны быть направлены на изучение предикторов и прогностических признаков рецидивирования и персистирования процесса, различий в микробиоте влагалища у пациенток с рецидивирующим и персистирующим БВ.
Ключевые слова: бактериальный вагиноз, терапия бактериального вагиноза, микробиота влагалища, микробиота
Keywords: bacterial vaginosis, bacterial vaginosis therapy, vaginal microbiota, microbiota
Ключевые слова: бактериальный вагиноз, терапия бактериального вагиноза, микробиота влагалища, микробиота
________________________________________________
Keywords: bacterial vaginosis, bacterial vaginosis therapy, vaginal microbiota, microbiota
Полный текст
Список литературы
1. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14. DOI:10.1038/nature11234
2. Centers for Disease Control and Prevention. STD Treatment Guidelines, 2015.
3. Bautista CT, Wurapa E, Sateren WB, et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016;3:4.
4. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis. 2016;214(Suppl. 1):S14-20.
5. Прилепская В.Н., Кира Е.Ф., Гомберг М.А., и др. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин.
М., 2019 [Prilepskaia VN, Kira EF, Gomberg MA, et al. Federal clinical guidelines. Diagnosis and treatment of diseases accompanied by pathological secretions from the genital tract of women. Moscow, 2019 (in Russian)].
6. Villaseca R, Ovalle A, Amaya F, et al. Vaginal infections in a Family Health Clinic in the Metropolitan Region, Chile. Rev Chilena Infectol. 2015;32(1):30-6.
7. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-23.
8. Klatt TE, Cole DC, Eastwood DC, Barnabei VM. Factors associated with recurrent bacterial vaginosis. J Reprod Med. 2010;55(1-2):55-61.
9. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-7.
10. Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214(1):1-5. DOI:10.1093/infdis/jiw121
11. Ranjit E, Raghubanshi BR, Maskey S, Parajuli P. Prevalence of Bacterial Vaginosis and Its Association with Risk Factors among Nonpregnant Women: A Hospital Based Study. Int J Microbiol. 2018;2018:8349601.
12. Guedou FA, Van Damme L, Deese J, et al. Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis. 2013;13:208.
13. Muzny CA, Sunesara IR, Austin EL, et al. Bacterial vaginosis among African American women who have sex with women. Sex Transm Dis. 2013;40(9):751.
14. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200(11):1662-70.
15. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-9.
16. Papanikolaou EG, Tsanadis G, Dalkalitsis N, Lolis D. Recurrent bacterial vaginosis in a virgin adolescent: a new method of treatment. Infection. 2002;30(6):403-4.
17. Дикке Г.Б. Значение оральной контрацепции в профилактике рецидивов бактериального вагиноза и снижении риска воспалительных заболеваний органов малого таза. Проблемы репродукции. 2017;23(4):32-6 [Dikke GB. Znachenie oral'noi kontratseptsii v profilaktike retsidivov bakterial'nogo vaginoza i snizhenii riska vospalitel'nykh zabolevanii organov malogo taza. Problemy reproduktsii. 2017;23(4):32-6 (in Russian)].
18. De Seta F, Restaino S, Banco R, et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol. 2014;30(11):830-5.
19. Madden T, Grentzer JM, Secura GM, et al. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217-22.
20. Hay P. Bacterial vaginosis. Medicine. 2014;42(7):359-63.
21. Holzman C, Leventhal JM, Qiu H, et al.; Group BVS. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health. 2001;91(10):1664-70.
22. Манухин И.Б., Фириченко С.В., Смирнова С.О., и др. Микробиота влагалища: диагностика, влияние на здоровье женщины и коррекция нарушений. М., 2015 [Manukhin IB. Vaginal microbiota: diagnosis, impact on women’s health and correction of disorders. Moscow, 2015 (in Russian)].
23. Dahal P, Jhendi S, Pun CM, Maharjan L. Assessment of Risk Factors and Medication Use for Infectious Vaginitis Among Females of Reproductive Age Visiting Maternity Hospital of Pokhara, Nepal. The Open Public Health Journal. 2017;10(1):140-7.
24. Baeten JM, Hassan WM, Chohan V, et al. Prospective study of correlates of vaginal Lactobacillus colonisation among high-risk HIV-1 seronegative women. Sex Transm Infect. 2009;85(5):348-53.
25. Marshall AO. Managing Recurrent Bacterial Vaginosis: Insights for Busy Providers. Sex Med Rev. 2015;3(2):88-92.
26. Martin DH, Marrazzo JM. The Vaginal Microbiome: Current Understanding and Future Directions. J Infect Dis. 2016;214(Suppl. 1):S36-41.
27. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
28. Sherrard J, Wilson J, Donders G, et al. European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-72.
29. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680-7. DOI:10.1073/pnas.1002611107
30. Ворошилина Е.С., Тумбинская Л.В., Донников А.Е., и др. Биоценоз влагалища с точки зрения количественной ПЦР: что есть норма? Акушерство и гинекология. 2011;1:57-65 [Voroshilina ES, Tumbinskaia LV, Donnikov AE, et al. Biotsenoz vlagalishcha s tochki zreniia kolichestvennoi PTsR: chto est' norma? Akusherstvo i ginekologiia. 2011;1:57-65 (in Russian)].
31. Reid G. Has knowledge of the vaginal microbiome altered approaches to health and disease? F1000Res. 2018;7:460. DOI:10.12688/f1000research.13706.1
32. Coudray MS, Madhivanan P. Bacterial Vaginosis – A Brief Synopsis of the Literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143-8.
33. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213-9.
34. Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol. 2019;S0002-9378(19):31007-5. DOI:10.1016/j.ajog.2019.08.008
35. Левочкина Л.Н., Варда С.В. Комплексная терапия бактериального вагиноза. Акушерство и гинекология. 2018:2 [Levochkina LN, Varda SV. Kompleksnaia terapiia bakterial'nogo vaginoza. Akusherstvo i ginekologiia. 2018:2 (in Russian)].
36. Сергиенко Г.С., Тазина Т.В., Жучков М.В. Возможности вагинального крема, содержащего клиндамицин и бутоконазол, в уменьшении риска рецидива урогенитального кандидоза у коморбидных пациенток с бактериальным вагинозом. Гинекология. 2018;20(1):68-70 [Sergiyenko GS, Tazina TV, Zhuchkov MV. The possibilities of clindamycin and butoconazole containing vaginal cream in reducing the risk of recurrence of urogenital candidiasis in comorbid patients with bacterial vaginosis. Gynecology. 2018;20(1):68-70 (in Russian)]. DOI:10.26442/2079-5696_20.1.68-70
37. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. DOI:10.1097/LGT.0b013e31829156eс
38. Дикке Г.Б. Бактериальный вагиноз: новые аспекты этиопатогенеза и выбора терапевтических стратегий. РМЖ. Мать и дитя. 2019;4:307-13 [Dikke GB. Bakterial'nyi vaginoz: novye aspekty etiopatogeneza i vybora terapevticheskikh strategii. RMZh. Mat' i ditia. 2019;4:307-13 (in Russian)].
39. Reid G. The development of probiotics for women’s health. Canad J Microbiol. 2017;63(4):269-77. DOI:10.1139/cjm-2016-0733
40. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015;15:292.
41. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8-11.
42. Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;18(6):702-8.
43. Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples – a pilot study. PLoS ONE. 2018;13(1):e0190199. DOI:10.1371/journal.pone.0190199
44. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Infect. 2012;39(10):822-30.
45. Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701. DOI:10.1002/14651858.CD011701.pub2
46. Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013;8(9):e73055. DOI:10.1371/journal.pone.0073055
47. Bradshaw CS, Tabrizi SN, Fairley CK, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194(6):828-36. DOI:10.1086/506621
48. Плахова К.И., Атрошкина М.Е., Ильина Е.Н., и др. Роль Atopobium vaginae при рецидивировании бактериального вагиноза. Вестник дерматологии и венерологии. 2007;5:9-13 [Plakhova KI, Atroshkina ME, Il'ina EN, et al. Rol' Atopobium vaginae pri retsidivirovanii bakterial'nogo vaginoza. Vestnik dermatologii i venerologii. 2007;5:9-13 (in Russian)].
49. Боровкова Л.В., Пономарева И.В., Косарева А.А., Колобова С.О. Роль A. vaginae в генезе рецидивирующего бактериального вагиноза. Медицинский альманах. 2016;5:83-5 [Borovkova LV, Ponomareva IV, Kosareva AA, Kolobova SO. Rol' A. vaginae v geneze retsidiviruiushchego bakterial'nogo vaginoza. Meditsinskii al'manakh. 2016;5:83-5 (in Russian)].
50. Lewis FM, Bernstein KT, Aral SO. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet Gynecol. 2017;129(4):643-54. DOI:10.1097/AOG.0000000000001932
51. Cox C, Watt AP, McKenna JP, Coyle PV. Mycoplasma hominis and Gardnerella vaginalis display a significant synergistic relationship in bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2016;35(3):481-7.
52. Bautista CT, Wurapa EK, Sanchez JL. Brief report: Associations between antecedent bacterial vaginosis and incident chlamydia and gonorrhea diagnoses, U.S. Army females, 2006–2012. MSMR. 2016;23(2):32-4.
53. Bautista CT, Wurapa EK, Sateren WB, et al. Association of Bacterial Vaginosis With Chlamydia and Gonorrhea Among Women in the U.S. Army. Am J Prev Med. 2017;52(5):632-9.
54. Gallo MF, Macaluso M, Warner L, et al. Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann Epidemiol. 2012;22(3):213-20.
55. Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014;210(11):1723-33.
56. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020;222(3):219-23. DOI:10.1016/j.ajog.2019.09.002
57. Haahr T, Jensen JS, Thomsen L, et al. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. 2016;31(4):795-803. DOI:10.1093/humrep/dew026
58. Brown RG, Marchesi JR, Lee YS, et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med. 2018;16(1):9.
59. Dingens AS, Fairfortune TS, Reed S, Mitchell C. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth. 2016;16(1):278.
60. Менухова Ю.Н. Бактериальный вагиноз: этиопатогенез, клинико-лабораторные особенности. Журн. акушерства и женских болезней. 2013;4:79-87 [Menukhova IuN. Bakterial'nyi vaginoz: etiopatogenez, kliniko-laboratornye osobennosti. Zhurn. akusherstva i zhenskikh boleznei. 2013;4:79-87 (in Russian)].
61. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis (BV) – associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115-9. DOI:10.1016/j.anaerobe.2017.05.005
62. Thellin O, Zorzi W, Zorzi D, et al. Lysozyme as a cotreatment during antibiotics use against vaginal infections: An in vitro study on Gardnerella vaginalis biofilm models. Int Microbiol. 2016;19(2):101-7. DOI:10.2436/20.1501.01.268
63. McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86:58-64. DOI:10.1016/j.colsurfb.2011.03.016
64. Mendling W, Palmeira-de-Oliveira A, Biber S, Prasauskas V. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1-6. DOI:10.1007/s00404-019-05142-8
2. Centers for Disease Control and Prevention. STD Treatment Guidelines, 2015.
3. Bautista CT, Wurapa E, Sateren WB, et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016;3:4.
4. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis. 2016;214(Suppl. 1):S14-20.
5. Prilepskaia VN, Kira EF, Gomberg MA, et al. Federal clinical guidelines. Diagnosis and treatment of diseases accompanied by pathological secretions from the genital tract of women. Moscow, 2019 (in Russian).
6. Villaseca R, Ovalle A, Amaya F, et al. Vaginal infections in a Family Health Clinic in the Metropolitan Region, Chile. Rev Chilena Infectol. 2015;32(1):30-6.
7. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-23.
8. Klatt TE, Cole DC, Eastwood DC, Barnabei VM. Factors associated with recurrent bacterial vaginosis. J Reprod Med. 2010;55(1-2):55-61.
9. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-7.
10. Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214(1):1-5. DOI:10.1093/infdis/jiw121
11. Ranjit E, Raghubanshi BR, Maskey S, Parajuli P. Prevalence of Bacterial Vaginosis and Its Association with Risk Factors among Nonpregnant Women: A Hospital Based Study. Int J Microbiol. 2018;2018:8349601.
12. Guedou FA, Van Damme L, Deese J, et al. Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis. 2013;13:208.
13. Muzny CA, Sunesara IR, Austin EL, et al. Bacterial vaginosis among African American women who have sex with women. Sex Transm Dis. 2013;40(9):751.
14. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200(11):1662-70.
15. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-9.
16. Papanikolaou EG, Tsanadis G, Dalkalitsis N, Lolis D. Recurrent bacterial vaginosis in a virgin adolescent: a new method of treatment. Infection. 2002;30(6):403-4.
17. Dikke GB. Znachenie oral'noi kontratseptsii v profilaktike retsidivov bakterial'nogo vaginoza i snizhenii riska vospalitel'nykh zabolevanii organov malogo taza. Problemy reproduktsii. 2017;23(4):32-6 (in Russian).
18. De Seta F, Restaino S, Banco R, et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol. 2014;30(11):830-5.
19. Madden T, Grentzer JM, Secura GM, et al. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217-22.
20. Hay P. Bacterial vaginosis. Medicine. 2014;42(7):359-63.
21. Holzman C, Leventhal JM, Qiu H, et al.; Group BVS. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health. 2001;91(10):1664-70.
22. Manukhin IB. Vaginal microbiota: diagnosis, impact on women’s health and correction of disorders. Moscow, 2015 (in Russian).
23. Dahal P, Jhendi S, Pun CM, Maharjan L. Assessment of Risk Factors and Medication Use for Infectious Vaginitis Among Females of Reproductive Age Visiting Maternity Hospital of Pokhara, Nepal. The Open Public Health Journal. 2017;10(1):140-7.
24. Baeten JM, Hassan WM, Chohan V, et al. Prospective study of correlates of vaginal Lactobacillus colonisation among high-risk HIV-1 seronegative women. Sex Transm Infect. 2009;85(5):348-53.
25. Marshall AO. Managing Recurrent Bacterial Vaginosis: Insights for Busy Providers. Sex Med Rev. 2015;3(2):88-92.
26. Martin DH, Marrazzo JM. The Vaginal Microbiome: Current Understanding and Future Directions. J Infect Dis. 2016;214(Suppl. 1):S36-41.
27. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
28. Sherrard J, Wilson J, Donders G, et al. European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-72.
29. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680-7. DOI:10.1073/pnas.1002611107
30. Voroshilina ES, Tumbinskaia LV, Donnikov AE, et al. Biotsenoz vlagalishcha s tochki zreniia kolichestvennoi PTsR: chto est' norma? Akusherstvo i ginekologiia. 2011;1:57-65 (in Russian).
31. Reid G. Has knowledge of the vaginal microbiome altered approaches to health and disease? F1000Res. 2018;7:460. DOI:10.12688/f1000research.13706.1
32. Coudray MS, Madhivanan P. Bacterial Vaginosis – A Brief Synopsis of the Literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143-8.
33. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213-9.
34. Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol. 2019;S0002-9378(19):31007-5. DOI:10.1016/j.ajog.2019.08.008
35. Levochkina LN, Varda SV. Kompleksnaia terapiia bakterial'nogo vaginoza. Akusherstvo i ginekologiia. 2018:2 (in Russian).
36. Sergiyenko GS, Tazina TV, Zhuchkov MV. The possibilities of clindamycin and butoconazole containing vaginal cream in reducing the risk of recurrence of urogenital candidiasis in comorbid patients with bacterial vaginosis. Gynecology. 2018;20(1):68-70 (in Russian). DOI:10.26442/2079-5696_20.1.68-70
37. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. DOI:10.1097/LGT.0b013e31829156eс
38. Dikke GB. Bakterial'nyi vaginoz: novye aspekty etiopatogeneza i vybora terapevticheskikh strategii. RMZh. Mat' i ditia. 2019;4:307-13 (in Russian).
39. Reid G. The development of probiotics for women’s health. Canad J Microbiol. 2017;63(4):269-77. DOI:10.1139/cjm-2016-0733
40. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015;15:292.
41. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8-11.
42. Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;18(6):702-8.
43. Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples – a pilot study. PLoS ONE. 2018;13(1):e0190199. DOI:10.1371/journal.pone.0190199
44. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Infect. 2012;39(10):822-30.
45. Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701. DOI:10.1002/14651858.CD011701.pub2
46. Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013;8(9):e73055. DOI:10.1371/journal.pone.0073055
47. Bradshaw CS, Tabrizi SN, Fairley CK, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194(6):828-36. DOI:10.1086/506621
48. Plakhova KI, Atroshkina ME, Il'ina EN, et al. Rol' Atopobium vaginae pri retsidivirovanii bakterial'nogo vaginoza. Vestnik dermatologii i venerologii. 2007;5:9-13 (in Russian).
49. Borovkova LV, Ponomareva IV, Kosareva AA, Kolobova SO. Rol' A. vaginae v geneze retsidiviruiushchego bakterial'nogo vaginoza. Meditsinskii al'manakh. 2016;5:83-5 (in Russian).
50. Lewis FM, Bernstein KT, Aral SO. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet Gynecol. 2017;129(4):643-54. DOI:10.1097/AOG.0000000000001932
51. Cox C, Watt AP, McKenna JP, Coyle PV. Mycoplasma hominis and Gardnerella vaginalis display a significant synergistic relationship in bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2016;35(3):481-7.
52. Bautista CT, Wurapa EK, Sanchez JL. Brief report: Associations between antecedent bacterial vaginosis and incident chlamydia and gonorrhea diagnoses, U.S. Army females, 2006–2012. MSMR. 2016;23(2):32-4.
53. Bautista CT, Wurapa EK, Sateren WB, et al. Association of Bacterial Vaginosis With Chlamydia and Gonorrhea Among Women in the U.S. Army. Am J Prev Med. 2017;52(5):632-9.
54. Gallo MF, Macaluso M, Warner L, et al. Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann Epidemiol. 2012;22(3):213-20.
55. Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014;210(11):1723-33.
56. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020;222(3):219-23. DOI:10.1016/j.ajog.2019.09.002
57. Haahr T, Jensen JS, Thomsen L, et al. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. 2016;31(4):795-803. DOI:10.1093/humrep/dew026
58. Brown RG, Marchesi JR, Lee YS, et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med. 2018;16(1):9.
59. Dingens AS, Fairfortune TS, Reed S, Mitchell C. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth. 2016;16(1):278.
60. Menukhova IuN. Bakterial'nyi vaginoz: etiopatogenez, kliniko-laboratornye osobennosti. Zhurn. akusherstva i zhenskikh boleznei. 2013;4:79-87 (in Russian).
61. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis (BV) – associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115-9. DOI:10.1016/j.anaerobe.2017.05.005
62. Thellin O, Zorzi W, Zorzi D, et al. Lysozyme as a cotreatment during antibiotics use against vaginal infections: An in vitro study on Gardnerella vaginalis biofilm models. Int Microbiol. 2016;19(2):101-7. DOI:10.2436/20.1501.01.268
63. McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86:58-64. DOI:10.1016/j.colsurfb.2011.03.016
64. Mendling W, Palmeira-de-Oliveira A, Biber S, Prasauskas V. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1-6. DOI:10.1007/s00404-019-05142-8
2. Centers for Disease Control and Prevention. STD Treatment Guidelines, 2015.
3. Bautista CT, Wurapa E, Sateren WB, et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016;3:4.
4. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis. 2016;214(Suppl. 1):S14-20.
5. Прилепская В.Н., Кира Е.Ф., Гомберг М.А., и др. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин.
М., 2019 [Prilepskaia VN, Kira EF, Gomberg MA, et al. Federal clinical guidelines. Diagnosis and treatment of diseases accompanied by pathological secretions from the genital tract of women. Moscow, 2019 (in Russian)].
6. Villaseca R, Ovalle A, Amaya F, et al. Vaginal infections in a Family Health Clinic in the Metropolitan Region, Chile. Rev Chilena Infectol. 2015;32(1):30-6.
7. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-23.
8. Klatt TE, Cole DC, Eastwood DC, Barnabei VM. Factors associated with recurrent bacterial vaginosis. J Reprod Med. 2010;55(1-2):55-61.
9. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-7.
10. Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214(1):1-5. DOI:10.1093/infdis/jiw121
11. Ranjit E, Raghubanshi BR, Maskey S, Parajuli P. Prevalence of Bacterial Vaginosis and Its Association with Risk Factors among Nonpregnant Women: A Hospital Based Study. Int J Microbiol. 2018;2018:8349601.
12. Guedou FA, Van Damme L, Deese J, et al. Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis. 2013;13:208.
13. Muzny CA, Sunesara IR, Austin EL, et al. Bacterial vaginosis among African American women who have sex with women. Sex Transm Dis. 2013;40(9):751.
14. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200(11):1662-70.
15. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-9.
16. Papanikolaou EG, Tsanadis G, Dalkalitsis N, Lolis D. Recurrent bacterial vaginosis in a virgin adolescent: a new method of treatment. Infection. 2002;30(6):403-4.
17. Дикке Г.Б. Значение оральной контрацепции в профилактике рецидивов бактериального вагиноза и снижении риска воспалительных заболеваний органов малого таза. Проблемы репродукции. 2017;23(4):32-6 [Dikke GB. Znachenie oral'noi kontratseptsii v profilaktike retsidivov bakterial'nogo vaginoza i snizhenii riska vospalitel'nykh zabolevanii organov malogo taza. Problemy reproduktsii. 2017;23(4):32-6 (in Russian)].
18. De Seta F, Restaino S, Banco R, et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol. 2014;30(11):830-5.
19. Madden T, Grentzer JM, Secura GM, et al. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217-22.
20. Hay P. Bacterial vaginosis. Medicine. 2014;42(7):359-63.
21. Holzman C, Leventhal JM, Qiu H, et al.; Group BVS. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health. 2001;91(10):1664-70.
22. Манухин И.Б., Фириченко С.В., Смирнова С.О., и др. Микробиота влагалища: диагностика, влияние на здоровье женщины и коррекция нарушений. М., 2015 [Manukhin IB. Vaginal microbiota: diagnosis, impact on women’s health and correction of disorders. Moscow, 2015 (in Russian)].
23. Dahal P, Jhendi S, Pun CM, Maharjan L. Assessment of Risk Factors and Medication Use for Infectious Vaginitis Among Females of Reproductive Age Visiting Maternity Hospital of Pokhara, Nepal. The Open Public Health Journal. 2017;10(1):140-7.
24. Baeten JM, Hassan WM, Chohan V, et al. Prospective study of correlates of vaginal Lactobacillus colonisation among high-risk HIV-1 seronegative women. Sex Transm Infect. 2009;85(5):348-53.
25. Marshall AO. Managing Recurrent Bacterial Vaginosis: Insights for Busy Providers. Sex Med Rev. 2015;3(2):88-92.
26. Martin DH, Marrazzo JM. The Vaginal Microbiome: Current Understanding and Future Directions. J Infect Dis. 2016;214(Suppl. 1):S36-41.
27. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
28. Sherrard J, Wilson J, Donders G, et al. European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-72.
29. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680-7. DOI:10.1073/pnas.1002611107
30. Ворошилина Е.С., Тумбинская Л.В., Донников А.Е., и др. Биоценоз влагалища с точки зрения количественной ПЦР: что есть норма? Акушерство и гинекология. 2011;1:57-65 [Voroshilina ES, Tumbinskaia LV, Donnikov AE, et al. Biotsenoz vlagalishcha s tochki zreniia kolichestvennoi PTsR: chto est' norma? Akusherstvo i ginekologiia. 2011;1:57-65 (in Russian)].
31. Reid G. Has knowledge of the vaginal microbiome altered approaches to health and disease? F1000Res. 2018;7:460. DOI:10.12688/f1000research.13706.1
32. Coudray MS, Madhivanan P. Bacterial Vaginosis – A Brief Synopsis of the Literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143-8.
33. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213-9.
34. Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol. 2019;S0002-9378(19):31007-5. DOI:10.1016/j.ajog.2019.08.008
35. Левочкина Л.Н., Варда С.В. Комплексная терапия бактериального вагиноза. Акушерство и гинекология. 2018:2 [Levochkina LN, Varda SV. Kompleksnaia terapiia bakterial'nogo vaginoza. Akusherstvo i ginekologiia. 2018:2 (in Russian)].
36. Сергиенко Г.С., Тазина Т.В., Жучков М.В. Возможности вагинального крема, содержащего клиндамицин и бутоконазол, в уменьшении риска рецидива урогенитального кандидоза у коморбидных пациенток с бактериальным вагинозом. Гинекология. 2018;20(1):68-70 [Sergiyenko GS, Tazina TV, Zhuchkov MV. The possibilities of clindamycin and butoconazole containing vaginal cream in reducing the risk of recurrence of urogenital candidiasis in comorbid patients with bacterial vaginosis. Gynecology. 2018;20(1):68-70 (in Russian)]. DOI:10.26442/2079-5696_20.1.68-70
37. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. DOI:10.1097/LGT.0b013e31829156eс
38. Дикке Г.Б. Бактериальный вагиноз: новые аспекты этиопатогенеза и выбора терапевтических стратегий. РМЖ. Мать и дитя. 2019;4:307-13 [Dikke GB. Bakterial'nyi vaginoz: novye aspekty etiopatogeneza i vybora terapevticheskikh strategii. RMZh. Mat' i ditia. 2019;4:307-13 (in Russian)].
39. Reid G. The development of probiotics for women’s health. Canad J Microbiol. 2017;63(4):269-77. DOI:10.1139/cjm-2016-0733
40. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015;15:292.
41. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8-11.
42. Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;18(6):702-8.
43. Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples – a pilot study. PLoS ONE. 2018;13(1):e0190199. DOI:10.1371/journal.pone.0190199
44. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Infect. 2012;39(10):822-30.
45. Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701. DOI:10.1002/14651858.CD011701.pub2
46. Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013;8(9):e73055. DOI:10.1371/journal.pone.0073055
47. Bradshaw CS, Tabrizi SN, Fairley CK, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194(6):828-36. DOI:10.1086/506621
48. Плахова К.И., Атрошкина М.Е., Ильина Е.Н., и др. Роль Atopobium vaginae при рецидивировании бактериального вагиноза. Вестник дерматологии и венерологии. 2007;5:9-13 [Plakhova KI, Atroshkina ME, Il'ina EN, et al. Rol' Atopobium vaginae pri retsidivirovanii bakterial'nogo vaginoza. Vestnik dermatologii i venerologii. 2007;5:9-13 (in Russian)].
49. Боровкова Л.В., Пономарева И.В., Косарева А.А., Колобова С.О. Роль A. vaginae в генезе рецидивирующего бактериального вагиноза. Медицинский альманах. 2016;5:83-5 [Borovkova LV, Ponomareva IV, Kosareva AA, Kolobova SO. Rol' A. vaginae v geneze retsidiviruiushchego bakterial'nogo vaginoza. Meditsinskii al'manakh. 2016;5:83-5 (in Russian)].
50. Lewis FM, Bernstein KT, Aral SO. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet Gynecol. 2017;129(4):643-54. DOI:10.1097/AOG.0000000000001932
51. Cox C, Watt AP, McKenna JP, Coyle PV. Mycoplasma hominis and Gardnerella vaginalis display a significant synergistic relationship in bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2016;35(3):481-7.
52. Bautista CT, Wurapa EK, Sanchez JL. Brief report: Associations between antecedent bacterial vaginosis and incident chlamydia and gonorrhea diagnoses, U.S. Army females, 2006–2012. MSMR. 2016;23(2):32-4.
53. Bautista CT, Wurapa EK, Sateren WB, et al. Association of Bacterial Vaginosis With Chlamydia and Gonorrhea Among Women in the U.S. Army. Am J Prev Med. 2017;52(5):632-9.
54. Gallo MF, Macaluso M, Warner L, et al. Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann Epidemiol. 2012;22(3):213-20.
55. Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014;210(11):1723-33.
56. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020;222(3):219-23. DOI:10.1016/j.ajog.2019.09.002
57. Haahr T, Jensen JS, Thomsen L, et al. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. 2016;31(4):795-803. DOI:10.1093/humrep/dew026
58. Brown RG, Marchesi JR, Lee YS, et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med. 2018;16(1):9.
59. Dingens AS, Fairfortune TS, Reed S, Mitchell C. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth. 2016;16(1):278.
60. Менухова Ю.Н. Бактериальный вагиноз: этиопатогенез, клинико-лабораторные особенности. Журн. акушерства и женских болезней. 2013;4:79-87 [Menukhova IuN. Bakterial'nyi vaginoz: etiopatogenez, kliniko-laboratornye osobennosti. Zhurn. akusherstva i zhenskikh boleznei. 2013;4:79-87 (in Russian)].
61. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis (BV) – associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115-9. DOI:10.1016/j.anaerobe.2017.05.005
62. Thellin O, Zorzi W, Zorzi D, et al. Lysozyme as a cotreatment during antibiotics use against vaginal infections: An in vitro study on Gardnerella vaginalis biofilm models. Int Microbiol. 2016;19(2):101-7. DOI:10.2436/20.1501.01.268
63. McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86:58-64. DOI:10.1016/j.colsurfb.2011.03.016
64. Mendling W, Palmeira-de-Oliveira A, Biber S, Prasauskas V. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1-6. DOI:10.1007/s00404-019-05142-8
________________________________________________
2. Centers for Disease Control and Prevention. STD Treatment Guidelines, 2015.
3. Bautista CT, Wurapa E, Sateren WB, et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016;3:4.
4. Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis. 2016;214(Suppl. 1):S14-20.
5. Prilepskaia VN, Kira EF, Gomberg MA, et al. Federal clinical guidelines. Diagnosis and treatment of diseases accompanied by pathological secretions from the genital tract of women. Moscow, 2019 (in Russian).
6. Villaseca R, Ovalle A, Amaya F, et al. Vaginal infections in a Family Health Clinic in the Metropolitan Region, Chile. Rev Chilena Infectol. 2015;32(1):30-6.
7. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-23.
8. Klatt TE, Cole DC, Eastwood DC, Barnabei VM. Factors associated with recurrent bacterial vaginosis. J Reprod Med. 2010;55(1-2):55-61.
9. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-7.
10. Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214(1):1-5. DOI:10.1093/infdis/jiw121
11. Ranjit E, Raghubanshi BR, Maskey S, Parajuli P. Prevalence of Bacterial Vaginosis and Its Association with Risk Factors among Nonpregnant Women: A Hospital Based Study. Int J Microbiol. 2018;2018:8349601.
12. Guedou FA, Van Damme L, Deese J, et al. Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis. 2013;13:208.
13. Muzny CA, Sunesara IR, Austin EL, et al. Bacterial vaginosis among African American women who have sex with women. Sex Transm Dis. 2013;40(9):751.
14. Fethers KA, Fairley CK, Morton A, et al. Early sexual experiences and risk factors for bacterial vaginosis. J Infect Dis. 2009;200(11):1662-70.
15. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-9.
16. Papanikolaou EG, Tsanadis G, Dalkalitsis N, Lolis D. Recurrent bacterial vaginosis in a virgin adolescent: a new method of treatment. Infection. 2002;30(6):403-4.
17. Dikke GB. Znachenie oral'noi kontratseptsii v profilaktike retsidivov bakterial'nogo vaginoza i snizhenii riska vospalitel'nykh zabolevanii organov malogo taza. Problemy reproduktsii. 2017;23(4):32-6 (in Russian).
18. De Seta F, Restaino S, Banco R, et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol Endocrinol. 2014;30(11):830-5.
19. Madden T, Grentzer JM, Secura GM, et al. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217-22.
20. Hay P. Bacterial vaginosis. Medicine. 2014;42(7):359-63.
21. Holzman C, Leventhal JM, Qiu H, et al.; Group BVS. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health. 2001;91(10):1664-70.
22. Manukhin IB. Vaginal microbiota: diagnosis, impact on women’s health and correction of disorders. Moscow, 2015 (in Russian).
23. Dahal P, Jhendi S, Pun CM, Maharjan L. Assessment of Risk Factors and Medication Use for Infectious Vaginitis Among Females of Reproductive Age Visiting Maternity Hospital of Pokhara, Nepal. The Open Public Health Journal. 2017;10(1):140-7.
24. Baeten JM, Hassan WM, Chohan V, et al. Prospective study of correlates of vaginal Lactobacillus colonisation among high-risk HIV-1 seronegative women. Sex Transm Infect. 2009;85(5):348-53.
25. Marshall AO. Managing Recurrent Bacterial Vaginosis: Insights for Busy Providers. Sex Med Rev. 2015;3(2):88-92.
26. Martin DH, Marrazzo JM. The Vaginal Microbiome: Current Understanding and Future Directions. J Infect Dis. 2016;214(Suppl. 1):S36-41.
27. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
28. Sherrard J, Wilson J, Donders G, et al. European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-72.
29. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680-7. DOI:10.1073/pnas.1002611107
30. Voroshilina ES, Tumbinskaia LV, Donnikov AE, et al. Biotsenoz vlagalishcha s tochki zreniia kolichestvennoi PTsR: chto est' norma? Akusherstvo i ginekologiia. 2011;1:57-65 (in Russian).
31. Reid G. Has knowledge of the vaginal microbiome altered approaches to health and disease? F1000Res. 2018;7:460. DOI:10.12688/f1000research.13706.1
32. Coudray MS, Madhivanan P. Bacterial Vaginosis – A Brief Synopsis of the Literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143-8.
33. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213-9.
34. Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol. 2019;S0002-9378(19):31007-5. DOI:10.1016/j.ajog.2019.08.008
35. Levochkina LN, Varda SV. Kompleksnaia terapiia bakterial'nogo vaginoza. Akusherstvo i ginekologiia. 2018:2 (in Russian).
36. Sergiyenko GS, Tazina TV, Zhuchkov MV. The possibilities of clindamycin and butoconazole containing vaginal cream in reducing the risk of recurrence of urogenital candidiasis in comorbid patients with bacterial vaginosis. Gynecology. 2018;20(1):68-70 (in Russian). DOI:10.26442/2079-5696_20.1.68-70
37. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. DOI:10.1097/LGT.0b013e31829156eс
38. Dikke GB. Bakterial'nyi vaginoz: novye aspekty etiopatogeneza i vybora terapevticheskikh strategii. RMZh. Mat' i ditia. 2019;4:307-13 (in Russian).
39. Reid G. The development of probiotics for women’s health. Canad J Microbiol. 2017;63(4):269-77. DOI:10.1139/cjm-2016-0733
40. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015;15:292.
41. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8-11.
42. Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;18(6):702-8.
43. Plummer EL, Vodstrcil LA, Danielewski JA, et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples – a pilot study. PLoS ONE. 2018;13(1):e0190199. DOI:10.1371/journal.pone.0190199
44. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Infect. 2012;39(10):822-30.
45. Amaya-Guio J, Viveros-Carreño DA, Sierra-Barrios EM, et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev. 2016;10:CD011701. DOI:10.1002/14651858.CD011701.pub2
46. Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013;8(9):e73055. DOI:10.1371/journal.pone.0073055
47. Bradshaw CS, Tabrizi SN, Fairley CK, et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis. 2006;194(6):828-36. DOI:10.1086/506621
48. Plakhova KI, Atroshkina ME, Il'ina EN, et al. Rol' Atopobium vaginae pri retsidivirovanii bakterial'nogo vaginoza. Vestnik dermatologii i venerologii. 2007;5:9-13 (in Russian).
49. Borovkova LV, Ponomareva IV, Kosareva AA, Kolobova SO. Rol' A. vaginae v geneze retsidiviruiushchego bakterial'nogo vaginoza. Meditsinskii al'manakh. 2016;5:83-5 (in Russian).
50. Lewis FM, Bernstein KT, Aral SO. Vaginal Microbiome and Its Relationship to Behavior, Sexual Health, and Sexually Transmitted Diseases. Obstet Gynecol. 2017;129(4):643-54. DOI:10.1097/AOG.0000000000001932
51. Cox C, Watt AP, McKenna JP, Coyle PV. Mycoplasma hominis and Gardnerella vaginalis display a significant synergistic relationship in bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2016;35(3):481-7.
52. Bautista CT, Wurapa EK, Sanchez JL. Brief report: Associations between antecedent bacterial vaginosis and incident chlamydia and gonorrhea diagnoses, U.S. Army females, 2006–2012. MSMR. 2016;23(2):32-4.
53. Bautista CT, Wurapa EK, Sateren WB, et al. Association of Bacterial Vaginosis With Chlamydia and Gonorrhea Among Women in the U.S. Army. Am J Prev Med. 2017;52(5):632-9.
54. Gallo MF, Macaluso M, Warner L, et al. Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann Epidemiol. 2012;22(3):213-20.
55. Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014;210(11):1723-33.
56. Soper DE. Bacterial vaginosis and surgical site infections. Am J Obstet Gynecol. 2020;222(3):219-23. DOI:10.1016/j.ajog.2019.09.002
57. Haahr T, Jensen JS, Thomsen L, et al. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. 2016;31(4):795-803. DOI:10.1093/humrep/dew026
58. Brown RG, Marchesi JR, Lee YS, et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med. 2018;16(1):9.
59. Dingens AS, Fairfortune TS, Reed S, Mitchell C. Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth. 2016;16(1):278.
60. Menukhova IuN. Bakterial'nyi vaginoz: etiopatogenez, kliniko-laboratornye osobennosti. Zhurn. akusherstva i zhenskikh boleznei. 2013;4:79-87 (in Russian).
61. Petrina MAB, Cosentino LA, Rabe LK, Hillier SL. Susceptibility of bacterial vaginosis (BV) – associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115-9. DOI:10.1016/j.anaerobe.2017.05.005
62. Thellin O, Zorzi W, Zorzi D, et al. Lysozyme as a cotreatment during antibiotics use against vaginal infections: An in vitro study on Gardnerella vaginalis biofilm models. Int Microbiol. 2016;19(2):101-7. DOI:10.2436/20.1501.01.268
63. McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86:58-64. DOI:10.1016/j.colsurfb.2011.03.016
64. Mendling W, Palmeira-de-Oliveira A, Biber S, Prasauskas V. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1-6. DOI:10.1007/s00404-019-05142-8
Авторы
А.Т. Уруймагова*, В.Н. Прилепская, Е.А. Межевитинова, А.Е. Донников, А.А. Иванова
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*ada.uruimagova@yandex.ru
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*ada.uruimagova@yandex.ru
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России, Москва, Россия
*ada.uruimagova@yandex.ru
________________________________________________
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*ada.uruimagova@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.